keyword
MENU ▼
Read by QxMD icon Read
search

cytoreductive surgery, HIPEC

keyword
https://www.readbyqxmd.com/read/27916169/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-hipec-in-elderly-patients-a-systematic-literature-review
#1
V López-López, P A Cascales-Campos, M A Schneider, J Gil, E Gil, N Rodriguez Gomez-Hidalgo, P Parrilla
The objective of this review was to evaluate morbidity, mortality and survival outcomes of elderly patients with peritoneal carcinomatosis. A systematic literature search and standardized data collection of primary research publications until June 2016 on morbidity, mortality and survival outcomes in adults aged 65 and older with peritoneal carcinomatosis treated with cytoreduction and HIPEC was performed, using PubMed, EMBASE, Scopus, ClinicalTrials.gov and Cochrane. Bibliographies of relevant reports were also hand-searched to identify all potentially eligible studies...
December 2016: Surgical Oncology
https://www.readbyqxmd.com/read/27916165/effectiveness-and-failures-of-a-fast-track-protocol-after-cytoreduction-and-hyperthermic-intraoperative-intraperitoneal-chemotherapy-in-patients-with-peritoneal-surface-malignancies
#2
REVIEW
P A Cascales-Campos, P A Sánchez-Fuentes, J Gil, E Gil, V López-López, N Rodriguez Gomez-Hidalgo, D Fuentes, P Parrilla
BACKGROUND: The aim of this study was to analyze the results short term perioperative of patients with peritoneal surface malignancies undergoing cytoreduction with peritonectomy and HIPEC under a controlled fast track protocol and evaluate the factors related to the failure of implementation of the protocol. PATIENTS AND METHOD: We prospectively analyzed a consecutive series of patients (N = 156) with peritoneal surface malignancies treated by cytoreductive surgery with peritonectomy procedures and HIPEC from September 2008 until December 2014, in whom a fast track protocol was implemented...
December 2016: Surgical Oncology
https://www.readbyqxmd.com/read/27913947/preclinical-evaluation-of-cathepsin-based-fluorescent-imaging-system-for-cytoreductive-surgery
#3
Carlos H F Chan, Lukas F Liesenfeld, Isabel Ferreiro-Neira, James C Cusack
BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a treatment option for peritoneal surface malignancies. The ability to detect microscopic foci of peritoneal metastasis intraoperatively may ensure the completeness of cytoreduction. In this study, we evaluated the suitability of a hand-held cathepsin-based fluorescent imaging system for intraoperative detection of appendiceal and colorectal peritoneal metastasis. METHODS: Peritoneal tumors and normal peritoneal tissues were collected from patients with appendiceal and colorectal peritoneal metastasis...
December 2, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27906610/infectious-complications-after-cytoreductive-surgery-and-hyperthermic-intra-peritoneal-chemotherapy
#4
Naciye Cigdem Arslan, Selman Sokmen, Vildan Avkan-Oguz, Funda Obuz, Aras Emre Canda, Cem Terzi, Mehmet Fuzun
BACKGROUND: The aim of this study was to review the post-operative and infectious complications and determine the risk factors associated with infections in cytoreductive surgery (CRS) and hyperthermic intra-peritoneal chemotherapy (HIPEC). PATIENTS AND METHODS: Between October 2007 and December 2013, patients who underwent CRS and HIPEC with a curative intent were included in the study. The Centers for Disease Control and Prevention's National Nosocomial Infections Surveillance System definitions were used to identify post-operative nosocomial infections...
December 1, 2016: Surgical Infections
https://www.readbyqxmd.com/read/27900630/current-delivery-of-hyperthermic-intraperitoneal-chemotherapy-with-cytoreductive-surgery-cs-hipec-and-perioperative-practices-an-international-survey-of-high-volume-surgeons
#5
Allison H Maciver, Eisar Al-Sukhni, Jesus Esquivel, Joseph J Skitzki, John M Kane, Valerie A Francescutti
BACKGROUND: Cytoreductive surgery and heated intraperitoneal chemotherapy (CS/HIPEC) is performed for selected indications at a limited number of specialized centers worldwide. Currently there is no standardized approach to the perioperative care process. We sought to capture current practices in the perioperative management of patients who undergo CS/HIPEC at high-volume centers. METHODS: Surgeon members of the American Society of Peritoneal Surface Malignancies working at high-volume CS/HIPEC centers (>10 cases/year) were invited to complete an online survey...
November 29, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27896512/cytoreduction-peritonectomy-procedures-combined-with-hyperthermic-intraperitoneal-chemotherapy-hipec-in-advanced-ovarian-cancer-retrospective-italian-multicenter-observational-study-of-511-cases
#6
Angelo Di Giorgio, Pierandrea De Iaco, Michele De Simone, Alfredo Garofalo, Giovanni Scambia, Antonio Daniele Pinna, Giorgio Maria Verdecchia, Luca Ansaloni, Antonio Macrì, Paolo Cappellini, Valerio Ceriani, Giorgio Giorda, Daniele Biacchi, Marco Vaira, Mario Valle, Paolo Sammartino
PURPOSE: The aim of this study was to help with the process of selecting patients with advanced ovarian cancer to undergo cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) by analyzing outcome data at distinct clinical time points reflecting the natural history of the disease. METHODS: In a retrospective Italian multicenter study investigating patients with advanced ovarian cancer who underwent CRS plus HIPEC between 1998 and 2014, we analyzed data for consecutive patients at eight treatment time points: primary debulking surgery (PDS); interval debulking surgery after partial response, after no response, and after a pathologic complete response to neoadjuvant chemotherapy; first recurrence with a progression-free interval >12, <12 months, or >12 months in patients who underwent further chemotherapy before CRS and HIPEC; and patients who underwent two or more CRS procedures and chemotherapy lines before CRS and HIPEC...
November 28, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27872533/role-of-imaging-in-peritoneal-surface-malignancies
#7
Santosh Krishnamurthy, Raghav Balasubramaniam
Imaging plays a vital role in the evaluation of peritoneal malignancies. The presence of peritoneal metastases (PM) alters tumor staging, with direct implications in treatment choice and prognosis. Cytoreductive surgery (CRS) and Hyperthermic intraperitoneal chemotherapy (HIPEC) as a combined modality treatment have led to prolonged survival and even cure in selected patients with PM. Better outcomes are seen in patients with limited disease spread. Therefore, early diagnosis of peritoneal tumor seeding is essential...
December 2016: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27866811/the-modified-glasgow-prognosis-score-predicts-for-overall-and-disease-free-survival-following-cytoreductive-surgery-and-hipec-in-patients-with-pseudomyxoma-peritonei-of-appendiceal-origin
#8
G H C Tan, C A Novo, S Dayal, K Chandrakumaran, F Mohamed, T Cecil, B J Moran
BACKGROUND: The modified Glasgow prognostic score (incorporating C-reactive protein and albumin) predicts survival in patients with gastro-intestinal tract cancer but has not been evaluated in patients with peritoneal malignancy. The aim was to evaluate the modified Glasgow score preoperatively in patients undergoing complete cytoreductive surgery (CCRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) of appendiceal origin. METHODS: Prospectively collected data from patients with PMP of appendiceal origin following CCRS and HIPEC between January 2007 and December 2011 were analysed...
October 31, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27864747/surgical-management-of-metastatic-colorectal-cancer-a-single-centre-experience-on-oncological-outcomes-of-pulmonary-resection-vs-cytoreductive-surgery-and-hipec
#9
Evelyn Yi Ting Wong, Grace Hwei Ching Tan, Deanna Wan Jie Ng, Tina Puay Theng Koh, Mrinal Kumar, Melissa Ching Ching Teo
PURPOSE: Metastasectomy is accepted as standard of care for selected patients with colorectal pulmonary metastases (CLM); however, the role of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases (CPM) is not universally accepted. We aim to compare oncological outcomes of patients with CLM and CPM after pulmonary resection and CRS-HIPEC, respectively, by comparing overall survival (OS) and disease-free survival (DFS). METHODS: A retrospective review of 49 CLM patients who underwent pulmonary resection, and 52 CPM patients who underwent CRS-HIPEC in a single institution from January 2003 to March 2015, was performed...
November 19, 2016: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/27855557/201-consecutive-cytoreductive-surgery-crs-and-hyperthermic-intraperitoneal-chemotherapy-hipec-procedures-in-a-single-asian-tertiary-centre
#10
Grace Tan, Claramae Chia, Mrinal Kumar, Su Pin Choo, John Chia, Chee Kian Tham, Khee Chee Soo, Melissa Teo
INTRODUCTION: Peritoneal carcinomatosis (PC) is increasingly being treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). We provide a review of a high-volume Asian institute's experience and survival outcomes with this procedure. METHODS: Data was prospectively collected from 201 consecutive CRS and HIPEC procedures performed in a single institution between April 2001 and November 2015. Our primary endpoints were OS and DFS, and secondary endpoints were morbidity and mortality...
November 17, 2016: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/27834358/intraperitoneal-immunotherapy-historical-perspectives-and-modern-therapy
#11
REVIEW
W F Morano, A Aggarwal, P Love, S D Richard, J Esquivel, W B Bowne
Intraperitoneal immunotherapy represents a novel strategy for the management of peritoneal metastases (PM). Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has remained the gold standard of treatment for patients with PM, yet despite optimal treatment, recurrence rates remain high and long-term survival poor. From Coley's toxins to immune checkpoint inhibitors, the wide variety of anticancer immunotherapeutic strategies are now garnering attention for control of regional disease of the peritoneal cavity...
November 2016: Cancer Gene Therapy
https://www.readbyqxmd.com/read/27792292/the-american-society-of-peritoneal-surface-malignancies-multi-institution-evaluation-of-1-051-advanced-ovarian-cancer-patients-undergoing-cytoreductive-surgery-and-hipec-an-introduction-of-the-peritoneal-surface-disease-severity-score
#12
Richard Sleightholm, Jason M Foster, Lynette Smith, Wim Ceelen, Marcello Deraco, Yusuf Yildirim, Edward Levine, Cristobal Muñoz-Casares, Olivier Glehen, Asish Patel, Jesus Esquivel
BACKGROUND: Standard treatment for ovarian epithelial cancer (OEC) consists of cytoreductive surgery (CRS) and a platinum-taxane chemotherapy combination. There is increasing interest in evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage IIIC/IV disease. The peritoneal surface disease severity score (PSDSS) was introduced as a basis to improve patient selection for this therapy in OEC. METHODS: The charts of 1,051 patients with advanced OEC who underwent CRS/HIPEC were retrospectively evaluated using the following preoperatively obtained criteria: symptoms, peritoneal dissemination, and tumor histology...
December 2016: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27779544/hyperthermic-intraperitoneal-perfusion-chemotherapy-and-cytoreductive-surgery-for-controlling-malignant-ascites-from-ovarian-cancer
#13
Mingchen Ba, Hui Long, Xiangliang Zhang, Yunqiang Tang, Yinbing Wu, Shuai Wang, Zhaofei Yan, Bohuo Zhang, Shuzhong Cui
BACKGROUND: Malignant ascites, a complication often seen in patients with ovarian cancer (OC), is difficult to treat, but hyperthermic intraperitoneal chemotherapy (HIPEC) has a good efficacy. OBJECTIVE: The aim of this study was to assess the efficacy of cytoreductive surgery (CRS) combined with HIPEC for controlling malignant ascites from OC. MATERIALS AND METHODS: From December 2009 until December 2014, 53 patients with OC and malignant ascites were treated with CRS and HIPEC...
November 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27741129/short-term-outcome-in-patients-treated-with-cytoreduction-and-hipec-compared-to-conventional-colon-cancer-surgery
#14
Geert A Simkens, Vic J Verwaal, Valery E Lemmens, Harm J Rutten, Ignace H de Hingh
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is an extensive procedure with considerable morbidity. Since only few hospitals perform CRS + HIPEC, this might lead to confounded outcomes between hospitals when audited. This study aims to compare outcomes between peritoneally metastasized (PM) colon cancer patients treated with CRS + HIPEC and patients undergoing conventional colon surgery. Furthermore, the impact of CRS + HIPEC on the risk of postoperative complications will be assessed, probably leading to better insight into how to report on postoperative outcomes in this distinct group of patients undergoing extensive colon surgery...
October 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27727026/best-practice-for-perioperative-management-of-patients-with-cytoreductive-surgery-and-hipec
#15
C Raspé, L Flöther, R Schneider, M Bucher, P Piso
Due to the significantly improved outcome and quality of life of patients with different tumor entities after cytoreductive surgery (CRS) and HIPEC, there is an increasing number of centers performing CRS and HIPEC procedures. As this procedure is technically challenging with potential high morbidity and mortality, respectively, institutional experience also in the anesthetic and intensive care departments is essential for optimal treatment and prevention of adverse events. Clinical pathways have to be developed to achieve also good results in more comorbid patients with border line indications and extensive surgical procedures...
September 28, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27718032/early-postoperative-intraperitoneal-chemotherapy-for-low-grade-appendiceal-mucinous-neoplasms-with-pseudomyxoma-peritonei-is-it-beneficial
#16
Yeqian Huang, Nayef A Alzahrani, Winston Liauw, Thamer B Traiki, David L Morris
BACKGROUND: There is little evidence for the use of early postoperative intraperitoneal chemotherapy (EPIC) in patients with low-grade appendiceal mucinous neoplasms (LAMNs) with pseudomyxoma peritonei (PMP). This study aims to assess the outcomes regarding the use of EPIC in a large cohort of patients with LAMNs with PMP uniformly treated by cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC), all of whom received hyperthermic intraperitoneal chemotherapy (HIPEC), and most of whom also received EPIC...
October 7, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27716880/peritoneal-metastases-from-adrenal-cortical-carcinoma-treated-by-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#17
Paul H Sugarbaker
PURPOSE: Adrenal cortical carcinoma is a rare cancer that often presents in an advanced stage. Not only systemic metastases but also local recurrence and peritoneal metastases prevent long-term survival in these patients. METHODS: A profoundly symptomatic patient with extensive peritoneal metastases and local recurrence was treated using cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with melphalan as the chemotherapy agent. RESULTS: Relative sparing of the small bowel within the abdomen and pelvis allowed a visible complete resection of all cancer...
September 27, 2016: Tumori
https://www.readbyqxmd.com/read/27705085/the-onset-of-intra-abdominal-adhesions-during-closed-abdomen-hyperthermic-intraperitoneal-chemotherapy
#18
Marco Lotti, Michela Giulii Capponi, Luca Campanati, Elia Poiasina, Luca Ansaloni, Eugenio Poletti, Luigi Frigerio
INTRODUCTION: Hyperthermic intraperitoneal chemotherapy (HIPEC) is delivered after cytoreductive surgery (CRS) in selected patients with peritoneal carcinomatosis. The closed-abdomen technique, preferred by many centers, prevents heat loss and drug spillage, but does not warrant homogeneous distribution of the perfusion fluid (PF). The hypothesized formation of intra-abdominal adhesions during the closed-abdomen perfusion period has never been described. MATERIALS AND METHODS: From March 2014 to April 2016, 10 consecutive patients with peritoneal carcinomatosis, selected for CRS, underwent the Laparoscopy-Enhanced HIPEC technique to explore the abdominal cavity during the perfusion...
October 5, 2016: Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A
https://www.readbyqxmd.com/read/27687746/unresectability-during-open-surgical-exploration-in-planned-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#19
Zachary Zihui Yong, Grace Hwei Ching Tan, Joelle Fui Sze Wong, Cindy Lim, Khee Chee Soo, Melissa Ching Ching Teo
BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are the treatment of choice for selected patients with peritoneal metastasis. Despite a stringent selection process, some patients were found to be unresectable only at surgery, which leads to disappointment and poor utilisation of limited infrastructural resources. This study aims to determine the pre-operative factors associated with unresectability in planned CRS and HIPEC. METHODS: Retrospective analysis of 172 consecutive patients eligible for CRS and HIPEC at the National Cancer Centre Singapore from April 2004 to May 2014 was performed...
December 2016: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/27682610/hyperthermic-intraperitoneal-chemotherapy-as-palliative-treatment-for-malignant-ascites-a-single-center-experience-and-a-review-of-the-literature
#20
Luigina Graziosi, Elisabetta Marino, Verena De Angelis, Alberto Rebonato, Annibale Donini
: Malignant ascites is an abnormal accumulation of fluid in the peritoneal cavity of patients with intraperitoneal cancer dissemination. This clinical condition could represent the terminal evolution of a lethal disease and could influence the prognosis, severely impairing the patients' quality of life. Treatment options include a multitude of different procedures with limited efficacy and some degree of risk; diuretics, paracentesis, peritoneo-venous shunts and intraperitoneal biologic agents like anti-VEGF molecules, metalloproteinase inhibitors and immunomodulators are included...
2016: Annali Italiani di Chirurgia
keyword
keyword
107684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"